
Continuing treatment results in a nearly 8% reduction in weight during a 48 week period.

Continuing treatment results in a nearly 8% reduction in weight during a 48 week period.

The approval represents the first ever therapy for chronic weight management for obesity caused by a trio of genetic deficiencies.

New findings suggest the "obesity paradox" may be explained by rates of exercise among women.

The daily oral capsule was shown to reduce overweight and obese patient weight by about 6% over 6 months.